Opening Day: Robinhood shares fall after IPO » 08:5307/3107/31/21
MXCT, RXST, TNYA, RANI, OMGA, IMRX, INAB, DOLE, HOOD, NUVL, ICVX, RSKD, COOK, RLYB, DUOL, MLNK, PWSC, CADL, SNTG, RNAZ, AGRI, MITQ, IINN, UNCY, SPRK, QNIU, CMSL, SCAN, AUTH, MS, GS, BCS, BAC, BLK, SPG
Shares of Robinhood…
|Over a week ago|
Opening Day: Wahlberg-backed gym owner F45 opens higher in public debut » 07:5907/1707/17/21
BLND, IMGO, STVN, RGC, TCRX, ERAS, SGHT, MCG, RPID, CULL, FXLV, SERA, IINN, UNCY, MF, ELEV, TKNO, MCW, GRPH, GHRS, DOCS, CFLT, GLUE, BHG, GRVI, MIRO, BON, FA, CXM, DDL, QNIU, CMSL, SPRK, SCAN, VTEX, GAMB, DUOL, AUTH, RXST, HOOD, MS, GS, BCS, BAC
Mark Wahlberg-backed F45…
Unicycive Therapeutics opens at $8.55, IPO priced at $5 per unit » 10:4707/1307/13/21
Unicycive Therapeutics (UNCY) priced 4.55M shares at $5.00 per unit. Each unit consists of one share of common stock and four-fifths of a warrant to purchase one share of common stock. The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. Roth Capital acted as lead book running manager for the offering. Unicycive is a clinical stage biotechnology company developing therapies for patients with kidney disease whose lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.
Unicycive Therapeutics 4.55M share IPO priced at $5.00 » 09:4607/1307/13/21
The revised deal range…
The revised deal range was $5.00-$6.00. Roth Capital acted as lead book running manager for the offering.
Unicycive Therapeutics 4.55M share IPO price range $5.00-$6.00 » 17:1707/0707/07/21
Roth Capital is acting as…
Roth Capital is acting as lead book running manager for the offering.